FDA Approval of CAPLYTA Has the Potential to Reset Treatment Expectations, Offering Hope for Remission in Adults With Major Depressive Disorder
November 07, 2025
November 07, 2025
RARITAN, New Jersey, Nov. 7 -- Johnson and Johnson Innovative Medicine issued the following news release on Nov. 6, 2025:
* * *
FDA approval of CAPLYTA(R) (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder
CAPLYTA(R), in combination with an oral antidepressant, demonstrated superior efficacy with a favorable safety and tolerability profile consistent with established indicat . . .
* * *
FDA approval of CAPLYTA(R) (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder
CAPLYTA(R), in combination with an oral antidepressant, demonstrated superior efficacy with a favorable safety and tolerability profile consistent with established indicat . . .